Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 26, 2026
Rhea-AI Summary
Amphastar Pharmaceuticals (NASDAQ:AMPH) will release fourth-quarter 2025 results after market close on Thursday, February 26, 2026 and will host a conference call the same day at 2:00 p.m. Pacific Time.
Investors can access the live call by dialing the provided toll-free or international numbers or via the company's Investors page at www.amphastar.com; a webcast replay will be posted within 24 hours.
Positive
- None.
Negative
- None.
News Market Reaction – AMPH
On the day this news was published, AMPH gained 0.81%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
AMPH slipped -0.42% while 2 tracked peers (e.g., EVO, PCRX) were also down (median move about -1.8%), indicating broader weakness in specialty/generic drug names.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 12 | Licensing deal | Positive | +6.0% | Exclusive AMP-110 license with milestones and royalties for ACTH analog. |
| Jan 07 | Conference appearance | Neutral | -1.1% | J.P. Morgan 2026 Healthcare Conference presentation and webcast availability. |
| Dec 15 | FDA approval | Positive | +4.1% | FDA approval of teriparatide injection ANDA judged bioequivalent to FORTEO. |
| Nov 24 | Conference appearance | Neutral | +2.7% | Piper Sandler Healthcare Conference fireside chat and 30-day webcast. |
| Nov 12 | Conference appearance | Neutral | +2.5% | Jefferies Global Healthcare Conference participation with webcast access. |
Stock has generally reacted positively or modestly to recent business development, FDA, and conference news.
Over the past few months, Amphastar has reported several notable events. An exclusive AMP-110 licensing deal on Jan 12, 2026 saw a +5.98% move, while multiple healthcare conference appearances in late 2025 produced smaller but mostly positive reactions. FDA approval of teriparatide injection on Dec 15, 2025 coincided with a +4.12% gain. Against this backdrop, today’s announcement simply schedules the Q4 2025 earnings release and call, fitting into a pattern of regular investor communication rather than a new fundamental catalyst.
Market Pulse Summary
This announcement schedules Amphastar’s Q4 2025 earnings release for February 26, 2026 and sets a 2:00 p.m. PT conference call. It signals routine transparency rather than a new operational development. With shares trading above the 200-day MA and about 12.7% below the $32.69 52-week high, investors may focus on upcoming revenue, margin, and pipeline updates during the call as the next fundamental catalysts.
Key Terms
intranasal medical
insulin api medical
group purchasing organizations technical
AI-generated analysis. Not financial advice.
RANCHO CUCAMONGA, CA / ACCESS Newswire / February 20, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2025 ended December 31, 2025, after the market closes on Thursday, February 26, 2026, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
To access the conference call, dial toll-free 877-407-0989, for international calls, dial 201-389-0921, ten minutes before the conference.
The call can also be accessed on the Investors page on the Company's website www.amphastar.com. The webcast replay of the call will be available on our Company website within 24 hours after the end of the live conference call.
Company Information
Amphastar is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin API products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information and resources are available at www.amphastar.com.
Forward Looking Statements
All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the impact of our products, including their potential for continued revenue growth, the strategic trajectory of and market for our product pipeline, our ability to leverage our existing expertise and technology, the impacts of any licensing agreements and ability to commercialize additional therapies, our manufacturing in-house expertise, our commercial momentum and position in the market. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission ("SEC"), including in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 3, 2025, in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 8, 2025, in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the SEC on August 7, 2025, in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the SEC on November 6, 2025, and our other filings or reports that we may file with the SEC. In particular, there can be no guarantee that our sales strategies will be successful, or that we will continue to experience significant sales of BAQSIMI®. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.
CONTACT:
Bill Peters
Chief Financial Officer
(909) 476-3416
SOURCE: Amphastar Pharmaceuticals, Inc.
View the original press release on ACCESS Newswire
FAQ
When will Amphastar (AMPH) release Q4 2025 earnings and hold the conference call?
How can investors join the Amphastar (AMPH) February 26, 2026 conference call?
Will Amphastar (AMPH) provide a replay of the February 26, 2026 earnings call?
What period do Amphastar's (AMPH) Q4 2025 results cover for the February 26, 2026 release?
Where can shareholders find Amphastar (AMPH) investor materials related to the February 26, 2026 call?
